Stevenage Bioscience Catalyst welcomes on board two new high-profile Non-Executive Directors

Dr Uday Phadke, co-founder and CEO Triple Chasm, and Dr Lynn Drummond, Chair of the Board of Governors and Pro-Chancellor at the University of Hertfordshire, have been appointed as Non-Executive Directors to Stevenage Bioscience Catalyst Board.

Announcing their appointments, Dr Sally Ann Forsyth OBE, CEO, Stevenage Bioscience Catalyst, said: “I am delighted to welcome Dr Phadke and Dr Drummond to the Board. They join us as we embark on a major expansion of the site with UBS Asset Management and Reef – which will create one of Europe’s largest life science hubs. This is a hugely exciting time for Stevenage Bioscience Catalyst and life sciences in the UK and our expert Board will help guide us through this important phase of development.” 

Dr Phadke has focused over the last three decades on how science and technology enabled innovation can be translated to deliver commercial impact. Author of two highly respected books, Dr Phadke is the originator of the Triple Chasm Approach, which challenges many of the commonly held perceptions about how innovations are transformed to create commercial, social, and environmental impact.

He is currently Chief Executive of both Cartezia and the Triple Chasm Company and serves on the Board of the UK R&D Society. Dr Phadke is a former Entrepreneur in Residence at the Judge Business School, Cambridge University, and was elected a Fellow of the RSA in 2018.

Speaking about his appointment, Dr Phadke, said: “I am delighted to join the SBC Board at this exciting point in its journey as it tackles the translation challenge for life-science companies. In particular I look forward to accelerating innovations in data-driven personalised diagnostics, therapeutics and health-care delivery enabled by new transcriptomic, genomic and proteomic insights.”

Dr Lynn Drummond has had a distinguished career in the pharmaceutical and life sciences sectors, spending 16 years as a Managing Director within Investment Banking for Rothschild. Prior to Rothschild, Lynn worked in the Cabinet Office in London as Private Secretary to the Chief Scientific Advisor.

Dr Drummond is currently Chair of the Board of Governors at the University of Hertfordshire; a non-Executive Director and Chair designate at Zotefoams plc and also works as a Board Mentor for Criticaleye. She has held additional Non-Executive Directorships at Venture Life Group plc; RPC Group plc; Infirst Healthcare; Shield Holdings AG; Allocate Software plc; Consort Medical plc; and Alimentary Health Ireland. Lynn has also been Chairman of Trustees for Breast Cancer Haven, and was on the University of Cambridge, Centre for Science and Policy Development Group.

Lynn holds a Bachelor of Science Degree in Chemistry from the University of Glasgow and a PhD in Biochemistry from the University of London. She is a Fellow of the Royal Society of Chemistry, and a Fellow of the Royal Society of Edinburgh.

Speaking about her appointment, Dr Drummond said: “I very much look forward to working with the team at SBC as they further develop their strategy to encourage and commercialise innovation.”

The Board is chaired by Jackie Hunter, who is also a Board Director at BenevolentAI and has over thirty years of experience in the bioscience research sector. Other Board Members include Jonathan Green, current Chair of the Board of One Nucleus, James Lawrence, Wellcome Trust Observer and James Wheatcroft, Head of Finance for Research and Medicinal Sciences & Technology at GSK R&D.

Meet the Board and Team here.